# MDACC Re-RT Pathway Implementation Plan

## Source: RSS Webinar MDACC Experience (Phan et al, Seminars in RO 2025)

---

## EXTRACTED DATA FROM SLIDES

### 1. Disease Free Interval (DFI) & Reirradiation Interval (RI)

**Key Thresholds:**
- **Minimum RI:** 6 months (based on spinal cord recovery)
- **Preferred RI:** >12 months for normal tissue healing and toxicity reduction
- **DFI <2 years:** Worse survival & disease control (MDACC, MIRI)
- **MIRI Class I:** RI >2 years + resected = most favorable prognosis
- **MDACC finding:** RI <2 years = poorer OS (but NOT toxicity or LC)

---

### 2. Location of Recurrence - Clinical Outcomes (Table 2)

**MDACC Series - 2-Year Outcomes by Subsite:**

| Outcome | Mucosal (N=185) | | Neck (N=109) | | Skull Base (N=132) | |
|---------|--------|--------|--------|--------|--------|--------|
| | **OP** | **NP** | **≤3cm** | **>3cm** | **SB** | **PNS** |
| **LC** | 77% | 76% | 89% | 68% | 86% | 73% |
| **RR** | 13% | 29% | 18% | **54%** | 8% | 15% |
| **DM** | 12% | 12% | 18% | **79%** | 26% | 17% |
| **OS** | **51%*** | 71% | 79% | **36%** | **83%** | 72% |
| **PFS** | **38%*** | 63% | 57% | **19%** | **67%** | 47% |

**Key Findings:**
- *OP/OC = poorer survival vs Skull Base/Neck (HR 1.69-2.92, p<0.01)
- **Neck >3cm = disaster (54% RR, 79% DM, 36% OS, 19% PFS)
- OOF recurrence ~25% across ALL subsites

---

### 3. Reirradiation Subsite Sensitivity (Toxicity)

**3 Risk Groups:**
- **Mucosa:** Highest severe toxicity (>50%)
- **Skull Base:** Lowest G3+ toxicity (≤10%)
- **Neck:** Intermediate; notable fibrosis and vessel risks

**Table 3 - Late G3+ Toxicity After Curative ReRT (<60cc):**

| Toxicity | **Mucosal** | | | | **Skull Base** | | | |
|----------|-----|------|------|-----|-----|------|------|-----|
| | All | SBRT | IMRT | PBT | All | SBRT | IMRT | PBT |
| **Late G3+** | **43%** | 21% | 44% | 23% | **11%** | **3%** | 13% | 20% |
| Late G4 | 11% | 15% | 19% | 0% | 0% | 0% | 0% | 0% |
| Late G5 | <2% | <2% | 0% | 3% | 0% | 0% | 0% | 0% |
| ORN | 16% | 7% | 19% | 7% | 8% | 7% | 10% | 7% |
| Severe Fibrosis | 19% | 13% | 22% | 21% | 5% | 3% | 7% | 20% |
| **Hemorrhage** | **2.2%** | **5.5%** | <2% | <2% | **0%** | 0% | 0% | 0% |

**Critical:** SBRT mucosal hemorrhage risk 5.5% vs 0% skull base!

---

### 4. Volume Thresholds

| Type | Volume | Modality | Outcome | Toxicity | Reference |
|------|--------|----------|---------|----------|-----------|
| **GTV** | <25cc | SBRT | Improved LC & OS | Less severe | Vargo et al |
| GTV | <15cc | IMRT | Improved LC | Less acute/late | Ward et al |
| **CTV** | <50cc | IMRT/PBT | NS | **Less late G3+** | Takiar, Phan |
| CTV | <25cc | IMRT/PBT | NS | **No G3+** | Holliday et al |
| **PTV** | >20cc | SBRT | **Reduced OS** | No difference | Diao K |
| PTV | <40cc | IMRT | Improved LC | Less | Lee N et al |
| PTV | >125cc | 2D-3D | Reduced OS | ↑ death risk | De Crevoisier |

**Key Threshold:** 
- Late G3+ Toxicity: **<21% when CTV <50cc** vs **>57% when CTV >50cc**

---

### 5. Carotid Blowout Syndrome (CBS) / Bleeding Event (BE)

**Overall Risk:**
- CBS/BE: **1.5% overall**, **3% in mucosal sites**

**Traditional Predictors:**
- Mucosal/skin ulceration
- Large tumor volume
- Inadequate dose (insufficient tumor control → progression → vessel erosion)
- Prior surgery/no flap
- Vessel invasion or encasement >180°
- Cumulative dose >120 Gy
- Short RI
- Infection/abscess prior to RT

**CBS/BE by Modality:**

| Modality | ALL | NO TUMOR | MUCOSAL | Range |
|----------|-----|----------|---------|-------|
| 2D/3D | 2.6% | - | - | 0-17% |
| **IMRT** | 2.3% | 1.3% | 2.8% | 0-7% |
| **PBT** | 2.5% | 1.6% | 3.6% | 2-11% |
| **SBRT LINAC** | 3.4% | 1.7% | 2.9% | 0-3% |
| **SBRT CK** | **8.5%** | - | - | 2-16% |

---

### 6. CBS/BE Risk Reduction Strategies (SBRT)

**SBRT Risk Reduction:**
- QOD fractionation (every other day)
- RI >6 months
- Minimize carotid volume receiving 20-30 Gy
- Dmax <30 Gy
- D0.5cc <20 Gy

**HYTEC Data (Grimm J et al, IJROBP 2020):**
- WITHOUT risk reduction: 10% risk when 0.5cc receives >20 Gy
- WITH risk reduction: 2.2% risk even when 1cc vessel receives >20 Gy

---

### 7. MDACC SBRT Carotid Constraints

| Structure | Constraint | Notes |
|-----------|------------|-------|
| **Carotid + Lingual arteries** | Dmax <30 Gy, V27 <0.5cc | If within 1cm of target |
| Lingual Vessel Avoid (<5mm from target) | <38 Gy Max | No hot spot in target |
| Lingual Vessel Avoid (>5mm from target) | <20 Gy Max | |
| Carotid Avoid - ipsilateral (<1cm) | <36 Gy max | Dose rate <5 Gy/fx |
| Carotid Avoid - ipsilateral (>1cm) | <30 Gy, V27 <0.5cc | Dose rate <6 Gy/fx |
| Carotid Avoid - ipsilateral (in target) | Avoid hot spot | V30 <1cc |

---

### 8. Toxicity by Subsite

| Subsite | Expected Complications | CBS/BE Risk | Vessels at Risk |
|---------|----------------------|-------------|-----------------|
| **NPX** | TLN, Clival ORN, Mucosal Necrosis, Eustachian, Hearing Loss | ↑↑↑ (High) | Petrous ICA, Cervical ICA |
| **OPX** | Mandibular ORN, Hyoid ORN, Lower CN palsy | ↑↑ (Moderate) | External CA, **Lingual Artery** (BOT), Ascending Pharyngeal (Tonsil) |
| **Neck** | RP: Lower CNs, Low: Brachial Plexus | ↑ (Lower) | ICA/CCA, Vertebral artery |

---

### 9. Adaptive SBRT for High-Risk Mucosal Sites

**High Risk Definition:**
- Tumor >25cc abutting lingual or carotid vessels
- Involvement of posterior pharyngeal wall, hyoid, or vallecula + prior dose >50 Gy

**Risk-Adapted Regimens (Prospective Registry):**
- 27 Gy in 3 fractions QOD (EQD2 ~51.3 Gy)
- 36 Gy in 4 fractions QOD (EQD2 ~68.4 Gy)
- ± pembrolizumab or cetuximab

**Early Results (n=54, median FU 16.8 mo):**
- 1-year LC: 84%
- G3+ toxicity: **9%** (vs 22% matched controls)

---

### 10. SBRT Dose Recommendations

**Consensus Thresholds:**
- **≥8 Gy/fraction** in 5 fractions = improved LC
- **≥9 Gy/fraction** over 3-4 fractions

**Clinical Evidence:**
| Institution | Regimen | Outcome |
|-------------|---------|---------|
| UPMC | ≥40 Gy/C | 2-year LC 58% vs 32% (<36 Gy) |
| MDACC | 42.5 Gy/5fx QOD | 2-year LC: 78% |
| Moffit Phase I | ≥40 Gy/5fx + cisplatin | Required for rHNSCC tumor control |

---

### 11. SBRT Dose Comparison Table (Multi-Institutional)

| Study | Year | N | Dose (Gy) | Fractionation | Median OS (mo) | Median PFS (mo) | Late G3+ (%) |
|-------|------|---|-----------|---------------|----------------|-----------------|--------------|
| **Diao, MDACC** | 2021 | 137 | 45 | 5 fx QOD | **44.3** | 11.8 | 15 |
| Vargo, multi-inst | 2018 | 414 | 40 | 5 fx QOD | 7.8 | - | 11.6 |
| Kress, Georgetown | 2015 | 85 | 30 | 5 fx daily | 8.6 | 8.6 | 5.9 |
| Vargo, Pittsburgh | 2014 | 132 | 44 | 5 fx QOD | 7 | - | 7 |
| Lartigau, France | 2013 | 60 | 36 | 6 fx QOD | 11.5 | 7.1 | 7 |
| Cengiz, Turkey | 2011 | 46 | 30 | 5 fx daily | 11.9 | 10.5 | 24.4 |
| Roh, Korea | 2009 | 36 | 30 | 3-5 fx daily | 16.2 | - | 8 |
| Siddiqui, Henry Ford | 2009 | 21 | 36 | 6 fx QOD | 6.7 | - | 24 |

**MDACC clearly superior outcomes with 45 Gy/5fx QOD regimen!**

---

### 12. EQD2 Comparison - SBRT Dose Options for OPSCC

| SBRT Regimen | BED₁₀ (Gy) | EQD₂ (Gy) | LC | G3+ Tox | Clinical Context |
|--------------|------------|-----------|-----|---------|------------------|
| **45 Gy/5fx** | 85.5/102.8 | 71.3/80 | ~90% | Higher | Non-mucosal high grade |
| **42.5 Gy/5fx** | 78.6/94.1 | 65.5/73.2 | ~85% | Moderate | High tox risk mucosal |
| **40 Gy/5fx** | 72/85.7 | 60/66.7 | 75-85% | Moderate | Large nodal reRT |
| **36 Gy/4fx** | 68.4/82.3 | 57/64 | 70-80% | Lower | Small tumors, non-SCC |
| **35 Gy/5fx** | 59.5/70 | 49.6/54.4 | 65-80% | Lower | Elderly/unfit, low-risk |
| **27 Gy/3fx** | 51.3/61.7 | 42.8/48 | 65-73% | Lowest | Palliative, high-risk mucosal |

---

## IMPLEMENTATION PLAN

### Phase 1: New "MDACC Pathway" Tab

**1.1 Flowchart/Decision Tree:**
```
Patient Assessment
    │
    ├─► Location of Recurrence
    │   ├─► Mucosal (OP, OC, NP, Larynx)
    │   ├─► Neck (≤3cm vs >3cm)
    │   └─► Skull Base (SB vs PNS)
    │
    ├─► Volume Assessment
    │   ├─► GTV: <15cc, 15-25cc, >25cc
    │   ├─► CTV: <25cc, 25-50cc, >50cc
    │   └─► PTV: <20cc, 20-40cc, >40cc
    │
    ├─► Reirradiation Interval
    │   ├─► <6 months (NOT recommended)
    │   ├─► 6-12 months (Caution)
    │   ├─► 12-24 months (Acceptable)
    │   └─► >24 months (Favorable - MIRI Class I eligible)
    │
    ├─► Modality Selection
    │   ├─► SBRT (if GTV <25cc, no skin invasion)
    │   ├─► IMRT (larger volumes, post-op)
    │   └─► PBT (skull base, pediatric, complex)
    │
    └─► Dose Selection (based on risk)
        ├─► Standard: 45 Gy/5fx QOD
        ├─► Moderate: 40-42.5 Gy/5fx
        ├─► De-escalated: 35-36 Gy/4-5fx
        └─► High-risk adaptive: 27 Gy/3fx
```

**1.2 Risk Calculators:**
- **CBS/BE Risk Calculator** based on:
  - Site (mucosal vs skull base vs neck)
  - Modality (IMRT, PBT, SBRT LINAC, SBRT CK)
  - Tumor proximity to carotid
  - Prior dose to carotid
  - Vessel encasement degree
  
- **Toxicity Risk Calculator:**
  - Volume input (GTV, CTV, or PTV)
  - Site
  - Modality
  - Output: Expected G3+, G4, G5, ORN, fibrosis, hemorrhage rates

**1.3 Outcome Predictor:**
- Input: Site, volume, modality, dose, RI
- Output: Expected 2-year LC, RR, DM, OS, PFS

---

### Phase 2: MDACC Prognostic Model

**Variables to Include:**
1. Location (Mucosal vs Neck vs Skull Base + subsite)
2. Volume (GTV/CTV/PTV)
3. RI (<6mo, 6-12mo, 12-24mo, >24mo)
4. Histology (SCC vs non-SCC)
5. Prior salvage surgery (yes/no)
6. Performance status (ECOG 0-1 vs 2)
7. Planned modality
8. Planned dose/fractionation

**Output:**
- Risk class (Favorable / Intermediate / Poor)
- Expected outcomes with confidence intervals
- Recommended approach
- CBS/BE risk category

---

### Phase 3: Interactive Features

1. **Dose Selection Tool:**
   - Input clinical scenario
   - Recommend optimal SBRT regimen from the EQD2 table
   - Show expected LC vs toxicity tradeoff

2. **Carotid Constraint Checker:**
   - Input planned doses to carotid
   - Compare to MDACC constraints
   - Flag violations
   - Calculate CBS risk

3. **Comparative Outcome Display:**
   - Show patient's predicted outcomes vs MDACC cohort
   - Kaplan-Meier style visualization

---

## WHAT I NEED FROM YOU

1. **Confirm the tab structure:**
   - Keep existing MIRI calculator as Tab 1?
   - Add MDACC Pathway as Tab 2?
   - Or merge/replace?

2. **Priority features:**
   - Which calculator first: CBS/BE risk? Toxicity? Outcomes?
   - Flowchart first or calculators first?

3. **Design preferences:**
   - Same teal theme?
   - Interactive flowchart (click through) or static?
   - Tables vs visual gauges for risk display?

4. **Data validation:**
   - Should I extract exact numbers from the slide tables for the calculators?
   - Any additional data sources to incorporate?

5. **Timeline:**
   - MVP by when?
   - Iterate after or full build first?

---

## REFERENCES

- Phan J et al. Seminars in Radiation Oncology 2025
- Grimm J et al. HYTEC, IJROBP 2020
- Diao K et al. Head Neck 2021
- Takiar V et al. IJROBP 2016
- Bagley AF et al. Head Neck 2020
- Ng SP et al. J Neurol Surg B Skull Base 2020
- Vargo et al. multi-institutional 2018
